You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Aiforia H2’25: Green shoots on the clinical side
Aiforia’s H2 revenue growth originated in Europe, where the company has successfully promoted the adoption of clinical models. The digital pathology market has developed more slowly than expected, and the investment's risk profile remains high. Analyst Antti Siltanen summarizes.